Cell Therapy News Volume 21.26 | Jul 20 2020

May 12, 2022

2020-07-20 | CTN 21.26

Cell Therapy News by STEMCELL Technologies

Vol. 21.26 – 20 July, 2020

TOP STORY

Tumor Response and Endogenous Immune Reactivity after Administration of HER2 CAR T Cells in a Child with Metastatic Rhabdomyosarcoma

Longitudinal immune-monitoring revealed remodeling of the T-cell receptor repertoire with immunodominant clones and serum autoantibodies reactive to oncogenic signaling pathway proteins.
[Nature Communications]

Full Article

PUBLICATIONSRanked by the impact factor of the journal

Human Forebrain Endothelial Cell Therapy for Psychiatric Disorders

Investigators generated human periventricular endothelial cells, using human pluripotent stem cell technology, and extensively characterized its molecular, cellular, and functional properties.
[Molecular Psychiatry]

Full Article

Allogeneic Adipose‐Derived Stem Cells Promote Ischemic Muscle Repair by Inducing M2 Macrophage Polarization via the HIF ‐1α/IL ‐10 Pathway

The transplantation of adipose‐derived mesenchymal stem cells (ASCs) into ischemic limbs induced increased blood flow reperfusion and limb salvage rate, whereas the depletion of tissue macrophages or transplanting HIF‐1α‐silenced ASCs inhibited the therapeutic effect.
[Stem Cells]

Abstract

Xenogeneic Mesenchymal Stem Cell Transplantation for Mandibular Defect Regeneration

To examine donor cell survival and host immune reaction, pig bone marrow‐derived mesenchymal stem cells were labeled with CM‐DiI, loaded onto gelatin sponge, and transplanted into 5‐mm mandibular defects of immunocompetent and T cell‐deficient athymic rats.
[Xenotransplantation]

Abstract

Increased Predominance of the Matured Ventricular Subtype in Embryonic Stem Cell-Derived Cardiomyocytes In Vivo

When transplanted into athymic rat hearts, proliferative capacity was lower for nodal-like than working-type cardiomyocytes with grafted cardiomyocytes eventually comprising only relatively matured ventricular cardiomyocytes.
[Scientific Reports]

Full Article

Genetically Modified Macrophages Accomplish Targeted Gene Delivery to the Inflamed Brain in Transgenic Parkin Q311X(A) Mice: Importance of Administration Routes

Researchers report fundamental changes in biodistribution and brain bioavailability of macrophage-based formulations upon different routes of administration: intravenous, intraperitoneal, or intrathecal injections.
[Scientific Reports]

Full Article

Enhanced Protection against Lipopolysaccharide‐Induced Acute Lung Injury by Autologous Transplantation of Adipose‐Derived Stromal Cells Combined with Low Tidal Volume Ventilation in Rats

Investigators aimed to determine whether a combined low tidal volume ventilation and adipose‐derived stromal cell treatment exerts additional protection against lipopolysaccharide‐induced acute lung injury in rats.
[Journal of Cellular Physiology]

Abstract

Intracoronary Administration of Allogeneic Cardiosphere-Derived Cells Immediately Prior to Reperfusion in Pigs with Acute Myocardial Infarction Reduces Infarct Size and Attenuates Adverse Cardiac Remodeling

Researchers performed a randomized, placebo-controlled study to assess the long-term efficacy of intracoronary infusion of five million allogeneic cardiosphere-derived cells, delivered at five minutes prior to reperfusion, in a porcine model of acute myocardial infarction.
[Journal of Cardiovascular Pharmacology and Therapeutics]

Abstract

Intra-Articular Xenogeneic Mesenchymal Stem Cell-Based Therapy Increases CD4⁺CD25⁺ Cells in Synovial Fluid

The authors aimed to identify the lymphocytic response to a xenogeneic human umbilical cord-derived mesenchymal stem cell-based cell therapy.
[Veterinary Immunology and Immunopathology]

Abstract

Learn about identifying genetic variants in hPSCs by watching Dr. Florian Merkle's webinar from the Nature Research Round Table on hPSC Quality

REVIEWS

Gene Therapy Development in Hearing Research in China

Investigators summarize the state of the field and focus mainly on the progress of gene therapy in animal model studies and the optimization of therapeutic strategies in China.
[Gene Therapy]

Abstract

INDUSTRY AND POLICY NEWS

Orchard Therapeutics Announces Orphan Drug and Rare Pediatric Disease Designations for OTL-203 for the Treatment of MPS-I

Orchard Therapeutics announced that the company has received both orphan drug designation and rare pediatric disease designation from the FDA for OTL-203, an ex vivo autologous hematopoietic stem cell gene therapy in development for the treatment of mucopolysaccharidosis type I.
[Orchard Therapeutics Limited]

Press Release

Positive Phase III Study Results for TRIKAFTA^® in People Ages 12 and Older with Cystic Fibrosis Who Have One Copy of the F508del Mutation and One Gating or Residual Function Mutation

Vertex Pharmaceuticals Incorporated announced results of a global Phase III study of TRIKAFTA^® in people with cystic fibrosis ages 12 years and older who have one copy of the F508del mutation and one gating mutation or one copy of the F508del mutation and one residual function mutation.
[Vertex Pharmaceuticals Incorporated]

Press Release

European Medicines Agency Validates Bristol Myers Squibb’s Application for CAR T Cell Therapy Lisocabtagene Maraleucel (liso-cel)

Bristol Myers Squibb announced that the European Medicines Agency has validated its Marketing Authorization Application for lisocabtagene maraleucel, an investigational CD19-directed chimeric antigen receptor T cell therapy, for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma and follicular lymphoma grade 3B after at least two prior therapies.
[Bristol Myers Squibb]

Press Release

FEATURED EVENT

Tumor Response and Endogenous Immune Reactivity after Administration of HER2 CAR T Cells in a Child with Metastatic Rhabdomyosarcoma

Human Forebrain Endothelial Cell Therapy for Psychiatric Disorders

Allogeneic Adipose‐Derived Stem Cells Promote Ischemic Muscle Repair by Inducing M2 Macrophage Polarization via the HIF ‐1α/IL ‐10 Pathway

Xenogeneic Mesenchymal Stem Cell Transplantation for Mandibular Defect Regeneration

Increased Predominance of the Matured Ventricular Subtype in Embryonic Stem Cell-Derived Cardiomyocytes In Vivo

Genetically Modified Macrophages Accomplish Targeted Gene Delivery to the Inflamed Brain in Transgenic Parkin Q311X(A) Mice: Importance of Administration Routes

Enhanced Protection against Lipopolysaccharide‐Induced Acute Lung Injury by Autologous Transplantation of Adipose‐Derived Stromal Cells Combined with Low Tidal Volume Ventilation in Rats

Intracoronary Administration of Allogeneic Cardiosphere-Derived Cells Immediately Prior to Reperfusion in Pigs with Acute Myocardial Infarction Reduces Infarct Size and Attenuates Adverse Cardiac Remodeling

Intra-Articular Xenogeneic Mesenchymal Stem Cell-Based Therapy Increases CD4⁺CD25⁺ Cells in Synovial Fluid

Gene Therapy Development in Hearing Research in China

Orchard Therapeutics Announces Orphan Drug and Rare Pediatric Disease Designations for OTL-203 for the Treatment of MPS-I

Positive Phase III Study Results for TRIKAFTA^® in People Ages 12 and Older with Cystic Fibrosis Who Have One Copy of the F508del Mutation and One Gating or Residual Function Mutation

European Medicines Agency Validates Bristol Myers Squibb’s Application for CAR T Cell Therapy Lisocabtagene Maraleucel (liso-cel)

International Society for Stem Cell Research (ISSCR): Advances in Stem Cell Research: From Single Cells to Organs

> See All Events

Engineer – Cell Therapy

Senior Scientist – Process Development Lab, Gene and Cell Therapy

Quality Control Manager – Gene and Cell Therapy

Scientific Project Manager – Neurofibromatosis Type 1 Gene Therapy

Postdoctoral Fellow – Immune and Stem Cell Engineering

Faculty Positions – Regenerative Medicine

> See All Jobs